# Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment

> **NCT06405217** · NA · RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- DTC - Differentiated Thyroid Cancer
- Thyroid Stimulating; Hormone, C
- Radiotherapy; Complications

## Interventions

- **DRUG:** Recombinant Human Thyroid Stimulating Hormone

## Key facts

- **NCT ID:** NCT06405217
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-20
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06405217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06405217, "Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06405217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*